Clinical Fellowships
This grant supports U.S. academic institutions in training physicians on the diagnosis, treatment, and research of Transthyretin-mediated Amyloidosis (ATTR) through clinical fellowships.
Funder: Alnylam Pharmaceuticals
Due Dates (Anticipated): August 2026 (Clinical Fellowships submission deadline, projected)
Funding Amounts: Up to $95,000 per institution for a one-year clinical fellowship; funds support salary and fellow benefits only.
Summary: Supports U.S. academic programs training physicians in Transthyretin-mediated Amyloidosis (ATTR) diagnosis, treatment, and research.
Key Information: Only U.S. ACGME-accredited institutions with active cardiology fellowship programs are eligible; funding is awarded to institutions, not individuals.
Description
Alnylam Pharmaceuticals' Clinical Fellowships provide funding to accredited U.S. academic healthcare organizations to support educational clinical programs focused on Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). The goal is to mentor and advance physician training in ATTR diagnosis, treatment, and research, fostering multidisciplinary collaboration to improve early recognition, optimize treatment pathways, and accelerate translation of scientific advances into patient-centered care. The fellowship is designed to enhance clinical and research skills through a robust curriculum, with institutions responsible for program design and fellow selection.
